Description

Oxaliplatin Concentrate for Infusions 5 mg/ml. 30 ml. (100 mg.) №1

Ingredients:

Oxaliplatin concentrate for infusions contains 5 mg of oxaliplatin per milliliter. Other ingredients may include water for injections and sodium hydroxide for pH adjustment.

Dosage:

For adults, the typical dosage of Oxaliplatin concentrate for infusions is calculated based on body surface area and is administered intravenously over a specified period as directed by a healthcare provider.

Indications:

Oxaliplatin concentrate for infusions is indicated for the treatment of advanced colorectal cancer in combination with other chemotherapy agents.

Contraindications:

Patients with a history of allergic reactions to platinum-containing compounds should not use Oxaliplatin concentrate for infusions. It is also contraindicated in patients with pre-existing severe renal impairment.

Directions:

Prior to administration, Oxaliplatin concentrate for infusions should be diluted in 250-500 ml of 5% dextrose solution and infused through a central line to minimize the risk of vein irritation.

Scientific Evidence:

Studies have shown that Oxaliplatin concentrate for infusions in combination with other chemotherapy agents has demonstrated efficacy in improving progression-free survival and overall survival rates in patients with advanced colorectal cancer.

Additional Information:

It is important to monitor patients receiving Oxaliplatin concentrate for infusions for signs of neurotoxicity, including peripheral neuropathy, and adjust the dosage or discontinue treatment if necessary to manage side effects.

The pharmacological effects of oxaliplatin involve the formation of platinum-DNA adducts, leading to DNA damage and cell death in rapidly dividing cancer cells. This mechanism of action makes it an effective cytotoxic agent against colorectal cancer.

Clinical trials have compared the effectiveness of oxaliplatin with other platinum-based chemotherapy drugs and have shown it to be equally or more effective in certain cancer types, with a more favorable side effect profile in some cases.